The generic version of Cambia is not yet available. However, it's possible that generic Cambia could be released after 16 June, 2026, following the expiry of the last patent.
Cambia is administered orally, and it is used for the acute treatment of migraine attacks with or without aura in adults. Its active ingredient, diclofenac potassium, helps in alleviating the symptoms associated with these conditions.
Cambia holds a total of 4 patents, none of which have expired. These patents, titled 'Diclofenac formulations and methods of use', are all set to expire on the same date - 16 June, 2026. These patents will directly affect the release of the Cambia generic. Below are the details of the patents: